P.O. Box 30192
Salt Lake City, UT 84120-0192
801-442-4912 or 800-442-3219
Fax 801-442-3006

selecthealth℠

PREAUTHORIZATION FORM

Irresa™
(gefitinib)

Therapeutic use: Treatment of locally advanced non-small cell lung cancer (NSCLC) after failure of both platinum-based and docetaxel chemotherapies.

Quantity Limit: 250mg per day, may increase to 500 mg daily if also receiving CYP3A4 inducer

Authorization Period: 12 months

Patient's name _____

Patient's ID# | | | | | | | | | DOB | | / | | / | | | | |

ICD-9 | | | | | | | | | | | _____

Physician's name_____

Physician's Ph# (| | |) | | | - | | | | | Fax# | | | - | | | |

Physician's signature_____ Date signed | | / | | / | | | | |

Supervising Physician's name_____ (Required if requesting provider is a nurse practitioner or physician assistant)

Please check "Yes" or "No" and respond to the following requests:			
1.	Has the member had a trial of platinum-based therapy? Platinum based therapies attempted: Name of Therapy | Duration of Therapy | Reason for Discontinuation | | | | | |	❑ Yes	❑ No
2.	Has the member had a trial of docetaxel-based therapy? Docetaxel based therapies attempted Name of Therapy | Duration of Therapy | Reason for Discontinuation | | | | | |	❑ Yes	❑ No

This form is intended for SelectHealth members only. All requests for preauthorization should be sent via fax to 1-801-442-3006. Missing, inaccurate, or incomplete information may cause a delay or denial of authorization.

© 2010 SelectHealth. All rights reserved. 1306 02/10
Last Updated: February 22, 2010